A Look at I-SPY 2: Novel Trial Design May Expand the Scope of Oncology Drug Development

Jane de Lartigue, PhD
Published: Wednesday, Apr 02, 2014
Breast Cancer Amid a growing recognition of the need to improve the process of developing oncology drugs, the novel I-SPY 2 clinical trial in breast cancer has demonstrated the potential to deliver new, effective treatment options more rapidly to patients who would most benefit while dramatically reducing the time and costs currently required to evaluate experimental therapies.

News of the first successful “graduations” from I-SPY 2 emerged as one of the major developments from the 2013 San Antonio Breast Cancer Symposium (SABCS) in December. Thus far, two compounds, the PARP inhibitor veliparib and the pan-ErbB inhibitor neratinib, are poised for phase III testing as a result of the program.

Need for Reforms Recognized

Currently, clinical trials in oncology are designed to test just one drug at a time, and generally are focused on treating patients with advanced, metastatic disease, with success in metastatic disease followed by investigations in the adjuvant setting. The process of getting a drug to market can take a decade or more, hundreds of millions of dollars, thousands of patients—and still face a high likelihood of failure.

I-SPY 1 Establishes Concept The I-SPY trials represent a significant example of efforts under way to address the need for fundamental change in the clinical trial system. The program is sponsored by the Biomarkers Consortium, a public-private biomedical research partnership managed by the Foundation for the National Institutes for Health (FNIH), and involves a collaboration among stakeholders from industry, academia, government, and others. These are phase II trials in the neoadjuvant setting in patients with locally advanced, stage II/III breast cancer, designed to rapidly codevelop novel agents and biomarker signatures.

I-SPY 2 At a Glance

Criteria for drug inclusion
  • Evidence of potential efficacy from preclinical/clinical studies
  • Tested and found safe in at least 1 phase I study with a taxane (or a taxane in combination with trastuzumab in patients with HER2-positive tumors)
  • Only 1 representative drug from a particular class
Criteria for “graduation”
  • Meet a threshold of 85% for predicted likelihood of success in a phase III trial of at least 300 patients
  • Double the log odds of achieving pathologic complete response
Active Clinical Investigations
Agent/Regimen Target (s) Company
Trebananib (AMG 386) ± trastuzumab (Herceptin) Angiopoietin 1/2-neutralizing peptibody + HER2-targeting agent Amgen
Ganitumab (AMG 479) + metformin Insulin-like growth factor 1 receptor inhibitor + anti hyperglycemic agent Amgen
MK-2206 ± trastuzumab Akt inhibitor + HER2-targeting agent Merck
Pertuzumab (Perjeta) + trastuzumab HER2-targeting agents Genentech
Pertuzumab + T-DM1 (Kadcyla) HER2-targeting agents Genentech
Graduated Agents
Veliparib (ABT-888) + carboplatin PARP inhibitor with platinum compound AbbVie
Neratinib Pan-ErbB inhibitor Puma Biotechnology

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.